Strategic Alliance Partnership | Contemporary Pediatrics connects pediatricians with peer-reviewed articles, guideline updates, and practice strategies for real-world clinical application.

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis. His vital signs in clinic were within normal limits, and ...

This approval of gepotidacin is the first in a new antibiotic class for the treatment of gonorrhoea approved in over 3 decades. Phase 3 data demonstrated noninferiority to ceftriaxone plus ...

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from November 2025. Another month has come and gone, and with it, several FDA approvals and regulatory ...

FDA approves Itvisma for patients 2 years and older with SMA, making it the first FDA-approved gene replacement therapy for this population. FDA approved Itvisma as the first gene replacement therapy ...

The investigational compound centanafadine to treat ADHD in children, adults, and adolescents, is a first-in-class NDSRI. Otsuka submitted a new drug application to the FDA for centanafadine to treat ...

Joshua Fitch is the senior editor for Contemporary Pediatrics. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown ...

For over 100 years, type 1 diabetes (T1D) has traditionally been diagnosed and treated at the onset of symptomatic hyperglycemia, often accompanied by severe disease, including life-threatening ...